Are We Overtreating DCIS?

December 6, 2014
Laura J. Esserman, MD, MBA
Laura J. Esserman, MD, MBA

With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.